Lipoprotein(a) plasma concentrations after renal transplantation: A prospective evaluation after 4 years of follow-up

Atherosclerosis

Volumn 144, Issue 2, 1999, Pages 381-391

  Kerschdorfer, Lisa ^a   König, Paul ^b   Neyer, Ulrich ^c   Bösmüller, Claudia ^b   Lhotta, Karl ^b   Auinger, Martin ^d   Hohenegger, Markus ^a   Riegler, Peter ^e   Margreiter, Raimund ^b   Utermann, Gerd ^a   Dieplinger, Hans ^a   Kronenberg, Florian ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GENERAL HOSPITAL LINZ   (Austria)

^e Zentralkrankenhaus Bozen   (Italy)

Author keywords

Apo(a) isoforms; Azathioprine; Cyclosporine; Immunosuppression; Lipoprotein(a); Renal disease; Renal transplantation

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN A; PREDNISOLONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0345004985     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00014-3     Document Type: Article

References (65)

1. Kronenberg F., Steinmetz A., Kostner G.M., Dieplinger H. Lipoprotein(a) in health and disease. Crit. Rev. Clin. Lab. Sci. 33:1996;495-543.
2. Utermann G. Lipoprotein(a). Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 7th edition:1995;1887-1912 McGraw-Hill, New York.
3. Wade D.P. Lipoprotein(a). Curr. Opin. Lipidol. 4:1993;244-249.
4. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80:1987;458-465.
5. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., Hobbs H.H. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87:1991;2153-2161.
6. Boerwinkle E., Leffert C.C., Lin J., Lackner C., Chiesa G., Hobbs H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90:1992;52-60.
7. Kraft H.G., Köchl S., Menzel H.J., Sandholzer C., Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum. Genet. 90:1992;220-230.
8. Kronenberg F., Utermann G., Dieplinger H. Lipoprotein(a) in renal disease. Am. J. Kidney Dis. 27:1996;1-25.
9. Kronenberg F., Trenkwalder E., Lingenhel A., Friedrich G., Lhotta K., Schober M., Moes N., König P., Utermann G., Dieplinger H. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J. Lipid Res. 38:1997;1755-1763.
10. Mooser V., Seabra M.C., Abedin M., Landschulz K.T., Marcovina S., Hobbs H.H. Apolipoprotein(a) kringle 4-containing fragments in urine. Relationship to plasma levels of lipoprotein(a). J. Clin. Invest. 97:1996;858-864.
11. Kostner K.M., Maurer G., Huber K., Stefenelli T., Dieplinger H., Steyrer E., Kostner G.M. Urinary excretion of apo(a) fragments - role in apo(a) catabolism. Arterioscler. Thromb. Vasc. Biol. 16:1996;905-911.
12. Mooser V., Marcovina S.M., White A.L., Hobbs H.H. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98:1996;2414-2424.
13. Cressman M.D., Heyka R.J., Paganini E.P., O'Neil J., Skibinski C.I., Hoff H.F. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 86:1992;475-482.
14. Kronenberg F., Kathrein H., König P., Neyer U., Sturm W., Lhotta K., Gröchenig E., Utermann G., Dieplinger H. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler. Thromb. 14:1994;1405-1411.
15. Webb A.T., Reaveley D.A., O'Donnell M., O'Connor B., Seed M., Brown E.A. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol. Dial. Transplant. 10:1995;354-357.
16. Koch M., Kutkuhn B., Trenkwalder E., Bach D., Grabensee B., Dieplinger H., Kronenberg F. Apolipoprotein B, fibrinogen, HDL cholesterol and apo(a) phenotypes predict coronary artery disease in hemodialysis patients. J. Am. Soc. Nephrol. 8:1997;1889-1898.
17. Wanner C., Bartens W., Walz G., Nauck M., Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol. Dial. Transplant. 10:1995;75-81.
18. Kronenberg F. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease. Curr. Opin. Nephrol. Hypertens. 7:1998;271-278.
19. Kronenberg F., Neyer U., Lhotta K., Trenkwalder E., Auinger M., Pribasnig A., Meisl T., König P., Dieplinger H. The low molecular weight apo(a) phenotype is an independent risk factor for coronary artery disease in hemodialysis patients. a prospective follow-up. J Am Soc Nephrol. 10:1999;1027-1036.
20. Dieplinger H., Lackner C., Kronenberg F., Sandholzer C., Lhotta K., Hoppichler F., Graf H., König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J. Clin. Invest. 91:1993;397-401.
21. Kronenberg F., König P., Neyer U., Auinger M., Pribasnig A., Lang U., Reitinger J., Pinter G., Utermann G., Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 6:1995;110-120.
22. Kronenberg F., König P., Lhotta K., Öfner D., Sandholzer C., Margreiter R., Dosch E., Utermann G., Dieplinger H. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler. Thromb. 14:1994;1399-1404.
23. Brown J.H., Anwar N., Short C.D., Bhatnagar D., Mackness M.I., Hunt L.P., Durrington P.N. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol. Dial. Transplant. 8:1993;863-867.
24. Süleymanlar G., Özben T., Sapan M., Yìlmaz H., Yakupoglu G., Karpuzoglu T. Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a). Transplant. Proc. 26:1994;2637-2638.
25. Sugahara S., Koyama I., Yoshikawa Y., Dohi Y., Omoto R. Lipid and lipoprotein(a) in renal transplant recipients. Transplant. Proc. 26:1994;2080-2081.
26. Azrolan N., Brown C.D., Thomas L., Hayek T., Zhao Z.H., Roberts K.G., Scheiner C., Friedman E.A. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler. Thromb. 14:1994;1393-1398.
27. Heimann P., Josephson M.A., Fellner S.K., Thistlethwaite J.R. Jr., Stuart F.P., Dasgupta A. Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am. J. Nephrol. 11:1991;470-474.
28. Webb A.T., Reaveley D.A., O'Donnell M., O'Connor B., Seed M., Brown E.A. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet. 341:1993;268-270.
29. Islam M.S., Bard J.M., Le Pogamp P., Leglise D., Bourbigot B., Rivalan J., Cledes J. Serum lipoprotein(a) in renal transplant recipients treated with cyclosporin monotherapy compared to conventional treatment. Nephrol. Dial. Transplant. 9:1994;332-333. Letter.
30. Irish A.B., Hayes J.M., Simons L.A., Simons J., Savdie E. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust. NZ. J. Med. 22:1992;243-248.
31. Lye W.C., Hughes K., Leong S.O., Tan C.C., Lee E.J.C. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant. Proc. 27:1995;977-978.
32. Barbagallo C.M., Averna M.R., Sparacino V., Galione A., Caputo F., Scafidi V., Amato S., Mancino C., Cefalù A.B., Notarbartolo A. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron. 64:1993;560-564.
33. Gault M.H., Longerich L.L., Purchase L., Harnett J., Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron. 70:1995;155-170.
34. Segarra A., Chacón P., Vilardell M., Piera L.L. Cyclosporin and serum lipids in renal transplant recipients. Lancet. 341:1993;766.
35. Sentí M., Puig J.M., Lloveras J., Aubó C., Mir M., Barbosa F., Oliveras A., Masramón J. Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients. Transplant. Proc. 29:1997;2404-2405.
36. Massy Z.A., Bader C.A., Chevalier A., Chauveau P., Zingraff J., Lambrey G., Drueke T.B., Jungers P., Kreis H., Lacour B. Serum Lp(a) levels in chronic renal failure and renal transplant patients. J. Nephrol. 7:1994;229-236.
37. Moore R., Thomas D., Morgan E., Wheeler D., Griffin P., Salaman J., Rees A. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant. Proc. 25:1993;1060-1061.
38. Buggy D., Breathnach A., Keogh B., Cooke T., Feely J. Lipoprotein(a) and treatment of chronic renal disease. J. Intern. Med. 234:1993;453-455.
39. Wheeler D.C., Morgan R., Thomas D.M., Seed M., Rees A., Moore R.H. Factors influencing plasma lipid profiles including lipoprotein(a) concentrations in renal transplanted recipients. Transplant. Int. 9:1996;221-226.
40. Black I.W., Wilcken D.E.L. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin. Chem. 38:1992;353-357.
41. Murphy B.G., McNamee P.T. Apolipoprotein(a) concentration decreases following renal transplantation. Nephrol. Dial. Transplant. 7:1992;174-175.
42. Kronenberg F., König P., Lhotta K., Königsrainer A., Sandholzer C., Utermann G., Dieplinger H. Cyclosporin and serum lipids in renal transplant recipients. Lancet. 341:1993;765.
43. Webb A., Misra M., Reaveley D., Seed M., Brown E. Effect of change of renal replacement therapy on plasma lipoprotein(a) concentration. Atherosclerosis. 109:1994;277. Abstract.
44. Yang C.W., Kim Y.S., Kim S.Y., Chang Y.S., Yoon Y.S., Bang B.K. Serum levels of lipoprotein(a) after renal transplantation: short-term follow-up. Nephron. 67:1994;364. Letter.
45. Segarra A., Chacón P., Martin M., Vilardell M., Vila J., Cotrina M., Fort J., Olmos A., Piera L.L. Serum lipoprotein (a) levels in patients with chronic renal failure - evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron. 69:1995;9-13.
46. Murphy B.G., Yong A., Brown J.H., McNamee P.T. Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis. 116:1995;241-245.
47. Von Ahsen N., Helmhold M., Eisenhauer T., Armstrong V.W., Oellerich M. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur. J. Clin. Invest. 26:1996;668-675.
48. Kronenberg F., Lobentanz E.-M., König P., Utermann G., Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J. Lipid Res. 35:1994;1318-1328.
49. Kronenberg F., Trenkwalder E., Kronenberg M.F., König P., Utermann G., Dieplinger H. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int. 54:1998;1385-1389.
50. Nankivell B.J., Chapman J.R., Allen R.D. Predicting glomerular filtration rate after simultaneous pancreas and kidney transplantation. Clin. Transplant. 9:1995;129-134.
51. Sandholzer C., Saha N., Kark J.D., Rees A., Jaross W., Dieplinger H., Hoppichler F., Boerwinkle E., Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler. Thromb. 12:1992;1214-1226.
52. Mölgaard J., Klausen I.C., Lassvik C., Færgeman O., Gerdes L.U., Olsson A.G. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler. Thromb. 12:1992;895-901.
53. Wild S.H., Fortmann S.P., Marcovina S.M. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler. Thromb. Vasc. Biol. 17:1997;239-245.
54. Kraft H.G., Lingenhel A., Bader G., Kostner G.M., Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis. 125:1996;53-61.
55. Budowle B., Giusti A.M., Waye J.S., Baechtel F.S., Fourney R.M., Adams D.E., Presley L.A., Deadman H.A., Monson K.L. Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. Am. J. Hum. Genet. 48:1991;841-855.
56. Zimmermann J., Herrlinger S., Pruy A., Wanner C. Mechanism of high serum lipoprotein(a) in hemodialysis patients. J. Am. Soc. Nephrol. 8:1997;260A. Abstract.
57. Brown J.H., Murphy B.G., Douglas A.F., Short C.D., Bhatnagar D., Mackness M.I., Hunt L.P., Doherty C.C., Durrington P.N. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron. 75:1997;277-282.
58. Hilbrands L.B., Demacker P.N.M., Hoitsma A.J., Stalenhoef A.F.H., Koene R.A.P. The effects of cyclosporine and prednisone on serum lipid and (apo)liproprotein levels in renal transplant recipients. J. Am. Soc. Nephrol. 5:1995;2073-2081.
59. Singh A., Tejani A. Hyperlipidemia in children: the role of uremia, steroids and cyclosporine therapy. Nephron. 74:1996;529-535.
60. Hunt B.J., Parratt R., Rose M., Yacoub M. Does cyclosporin affect lipoprotein(a) concentrations? Lancet. 343:1994;119-120.
61. Sturrock N.D.C., Lang C.C., MacFarlane L.J., Dockrell M.E.C., Ryan M., Webb D.J., Struthers A.D. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J. Hypertens. 13:1995;667-673.
62. De Sain-van der Velden M.G.M., Reijngoud D.J., Kaysen G.A., Gadellaa M.M., Voorbij H., Stellaard F., Koomans H.A., Rabelink T.J. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J. Am. Soc. Nephrol. 9:1998;1474-1481.
63. Appel G. Lipid abnormalities in renal disease. Kidney Int. 39:1991;169-183.
64. Massy Z.A., Kasiske B.L. Post-transplant hyperlipidemia: mechanisms and management. J. Am. Soc. Nephrol. 7:1996;971-977.
65. Kagan A., Bar-Khayim Y., Schafer Z., Fainaru M. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int. 37:1990;980-990.